Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Unity Biotechnology
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 28, 2021
UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting. UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma.